Anal Cancer (Oncology) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer – Drugs In Development, 2021, provides an overview of the Anal Cancer (Oncology) pipeline landscape.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area. Predisposing factors include HPV infections, smoking and lowered immunity.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anal Cancer – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Anal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 30, 21, 2 and 4 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Anal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Anal Cancer (Oncology).

– The pipeline guide reviews pipeline therapeutics for Anal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Anal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Anal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Anal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Anal Cancer (Oncology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Anal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Antiva Biosciences Inc

AstraZeneca Plc

Beijing Kangle Guardian Biotechnology Co Ltd

Beijing Shenzhou Cell Biotechnology Group Co Ltd

Bicara Therapeutics Inc

Biomimetix JV LLC

BNOAT Oncology Inc

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Cleveland BioLabs Inc

Cue Biopharma Inc

CytomX Therapeutics Inc

Eisai Co Ltd

Eli Lilly and Co

eTheRNA Immunotherapies NV

F. Hoffmann-La Roche Ltd

Fujifilm Holdings Corp

Genocea Biosciences Inc

Gilead Sciences Inc

Guangzhou BeBetter Medicine Technology Co Ltd

Hookipa Pharma Inc

IMV Inc

Incyte Corp

Invectys SA

ISA Pharmaceuticals BV

Merck & Co Inc

Merck KGaA

Mereo Biopharma Group Plc

Molecular Partners AG

Novartis AG

Oncolytics Biotech Inc

Onconova Therapeutics Inc

Ono Pharmaceutical Co Ltd

PDS Biotechnology Corp

Precigen Inc

Privo Technologies Inc

Rubius Therapeutics Inc

Sanofi

Shanghai De Novo Pharmatech Co Ltd

Shanghai Zerun Biotechnology Co Ltd

Shattuck Labs Inc

Sotio AS

SQZ Biotechnologies Co

Transgene SA

Treadwell Therapeutics Inc

Turnstone Biologics Inc

Virion Therapeutics LLC

Xencor Inc

Zymeworks Inc

Table of Contents

Table of Contents

Introduction

Anal Cancer - Overview

Anal Cancer - Therapeutics Development

Anal Cancer - Therapeutics Assessment

Anal Cancer - Companies Involved in Therapeutics Development

Anal Cancer - Drug Profiles

Anal Cancer - Dormant Projects

Anal Cancer - Discontinued Products

Anal Cancer - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Anal Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Anal Cancer – Pipeline by Antiva Biosciences Inc, 2021

Anal Cancer – Pipeline by AstraZeneca Plc, 2021

Anal Cancer – Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2021

Anal Cancer – Pipeline by Beijing Shenzhou Cell Biotechnology Group Co Ltd, 2021

Anal Cancer – Pipeline by Bicara Therapeutics Inc, 2021

Anal Cancer – Pipeline by Biomimetix JV LLC, 2021

Anal Cancer – Pipeline by BNOAT Oncology Inc, 2021

Anal Cancer – Pipeline by Boehringer Ingelheim International GmbH, 2021

Anal Cancer – Pipeline by Bristol-Myers Squibb Co, 2021

Anal Cancer – Pipeline by Cleveland BioLabs Inc, 2021

Anal Cancer – Pipeline by Cue Biopharma Inc, 2021

Anal Cancer – Pipeline by CytomX Therapeutics Inc, 2021

Anal Cancer – Pipeline by Eisai Co Ltd, 2021

Anal Cancer – Pipeline by Eli Lilly and Co, 2021

Anal Cancer – Pipeline by eTheRNA Immunotherapies NV, 2021

Anal Cancer – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Anal Cancer – Pipeline by Fujifilm Holdings Corp, 2021

Anal Cancer – Pipeline by Genocea Biosciences Inc, 2021

Anal Cancer – Pipeline by Gilead Sciences Inc, 2021

Anal Cancer – Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2021

Anal Cancer – Pipeline by Hookipa Pharma Inc, 2021

Anal Cancer – Pipeline by IMV Inc, 2021

Anal Cancer – Pipeline by Incyte Corp, 2021

Anal Cancer – Pipeline by Invectys SA, 2021

Anal Cancer – Pipeline by ISA Pharmaceuticals BV, 2021

Anal Cancer – Pipeline by Merck & Co Inc, 2021

Anal Cancer – Pipeline by Merck KGaA, 2021

Anal Cancer – Pipeline by Mereo Biopharma Group Plc, 2021

Anal Cancer – Pipeline by Molecular Partners AG, 2021

Anal Cancer – Pipeline by Novartis AG, 2021

Anal Cancer – Pipeline by Oncolytics Biotech Inc, 2021

Anal Cancer – Pipeline by Onconova Therapeutics Inc, 2021

Anal Cancer – Pipeline by Ono Pharmaceutical Co Ltd, 2021

Anal Cancer – Pipeline by PDS Biotechnology Corp, 2021

Anal Cancer – Pipeline by Precigen Inc, 2021

Anal Cancer – Pipeline by Privo Technologies Inc, 2021

Anal Cancer – Pipeline by Rubius Therapeutics Inc, 2021

Anal Cancer – Pipeline by Sanofi, 2021

Anal Cancer – Pipeline by Shanghai De Novo Pharmatech Co Ltd, 2021

Anal Cancer – Pipeline by Shanghai Zerun Biotechnology Co Ltd, 2021

Anal Cancer – Pipeline by Shattuck Labs Inc, 2021

Anal Cancer – Pipeline by Sotio AS, 2021

Anal Cancer – Pipeline by SQZ Biotechnologies Co, 2021

Anal Cancer – Pipeline by Transgene SA, 2021

Anal Cancer – Dormant Projects, 2021

Anal Cancer – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Anal Cancer, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Top 10 Routes of Administration, 2021

Number of Products by Stage and Top 10 Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports